SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30-40% reductions in heart failure hospitalisation, cardiovascular and all-cause deaths on empagliflozin were highly impressive and une...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer
2016
|